34 ....................................................................................................................................................................................................................................................................................................................................................................................................................................................................... Services for academic institutions and start-ups Our work is part of a collaborative ecosystem seeking to contribute to more successful academic pharma. Their focus on discovering new chemical entities for rare diseases either first in class or best in class drug candidates, is supported by our parternship. The nature of our work can potentially support their presence in the development to the market value chain by engaging with pharmaceutical companies which help them further with their discoveries. For over 10 years we have provided standalone services (chemistry and DMPK or standalone chemistry or standalone DMPK) to support startups, virtual groups, and academicians to achieve drug discovery and development projects. We continue to add infrastructure to enable academicians and support the project goals through exploratory studies in the areas of CNS drug discovery, PROTAC modalities, Antibody-drug conjugates, and prodrug research. As per the National Centre for Biotechnology Information, US, in 2021, 75% of the drugs accepted by the FDA were small molecules, with the dominant therapeutic area being oncology. Over 50% of these approvals were from small and mid-sized companies which require support from CDMOs for the commercialization of products. We are guided in our sustainability success as we align with our customer expectations In the current environment, we are continuously adapting our offerings and capabilities to suit the evolving requirements of our existing and prospective partners and to meet their expectations by undertaking critical moves such as: 1. Increasing process development capabilities--securing access to high containment synthesis 2. Developing capabilities in particle engineering 3. Exploring the potential of continuous processes 4. Adapting the production capacity for flexibility Accelerating development timelines Speed Scientific Excellence Environmental & Safety Risk Management Meeting Technical Needs Proactively meet process development demands Anticipating potential risks and avoiding potential liabilities by using the precautionary principle Developing APIs to suit the needs of bioequivalence and ease of formulation Addressing sustainability related queries in RFP/RFQ covering policies, external certifications, ratings, environment metrics etc. Efforts towards net zero in the value chain by taking action on reducing the Scope 1, 2, 3 emissions Report on environmental metrics and engage for performance improvement Assessment on EcoVadis platform and successful PSCI audits covering topics of Environment, Health & safety, Human rights & labour & ethics 2. Growing value-added strategic services in the CDMO space that help create a positive “customer experience” Our partnership credo has sustainability inbuilt for mutual success and growth. Critical sustainability expectations
RkJQdWJsaXNoZXIy MTIwMDc4NQ==